Plain-English translation of NCT06456593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called can help control moderate to severe Crohn's disease in people whose disease has not responded well to standard treatments. The study will compare at three different doses against placebo (an inactive pill) to see which dose works best and is safest. The trial will last about 100 weeks total, split into three phases: an initial 12-week treatment phase, a 40-week continuation phase, and an optional 48-week extension phase.
Crohn's disease is a serious condition that causes inflammation in the digestive tract, and many patients do not respond well to existing medications. This trial is being done to find out whether this new treatment can help people whose disease has become resistant to other therapies or who have experienced side effects from them.
You likely qualify if…
You likely don't qualify if…
You will take either the new medication or a placebo pill once daily by mouth. You will attend multiple clinic visits over approximately 100 weeks to have your disease activity checked, provide blood samples, and undergo colonoscopy procedures to monitor how well the treatment is working. The study includes three phases: a 12-week initial treatment phase to see if the medication helps, a 40-week continuation phase for those who respond well, and an optional 48-week extension phase to gather more safety information.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States